Current Hypertension Reports

, Volume 11, Issue 1, pp 7–9 | Cite as

ONTARGET: How much RAS inhibition is enough?

  • Alan B. Weder
Clinical Trials Report
  • 37 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kunz R, Friedrish C, Wolbers M, Mann JFE: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.PubMedGoogle Scholar
  2. 2.
    Barnett AH, Bain SC, Bouter P, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952–1961.PubMedCrossRefGoogle Scholar
  3. 3.
    Hollenberg NK, Parving H-H, Viberti G, et al.: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007, 25:1921–1926.PubMedCrossRefGoogle Scholar
  4. 4.
    Parving H-H, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 2008, 358:2433–2446.PubMedCrossRefGoogle Scholar
  5. 5.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.CrossRefGoogle Scholar
  6. 6.
    Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033.Google Scholar
  7. 7.
    The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefGoogle Scholar
  8. 8.
    Kaplan NM: Recent clinical trials: the good, the bad, and the misleading. Hypertension 2008, 52:608–609.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • Alan B. Weder

There are no affiliations available

Personalised recommendations